Patient-Derived Organoids Show Promise for Personalized Therapy in Pancreatic Cancer

Manuel Hidalgo Medina, MD, PhD Patient-derived organoids (PDOs) may possess the potential to personalize therapy and allow for the exclusion of ineffective drugs from combination regimens, reducing toxicity in patients with pancreatic cancer, according to preliminary results from the HOPE trial. 1 As such, it is anticipated that this […]

View Original Source at Patient-Derived Organoids Show Promise for Personalized Therapy in Pancreatic Cancer